Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 8월 27

Cytokinetics Inc

CYTKNASDAQ
Trade with Public
Trade with Public
$79.20
1.742.25%
가까이에: Aug 25, 5:00 PM EST
$79.25
1.792.31%
프리마켓: 4:00 AM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Cytokinetics Financials

Cytokinetics (CYTK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.63) by 7.98 percent. This is a 33.93 percent decrease over losses of $(1.12) per share from the
Benzinga Newsdesk

PRO
Cytokinetics Q1 EPS $(1.67) Misses $(1.64) Estimate, Sales $19.355M Beat $8.518M Estimate.

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(1.64) by 1.83 percent. This is a 22.79 percent decrease over losses of $(1.36) per share from the
Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

Cytokinetics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Cytokinetics Q4 EPS $(1.50) Misses $(1.45) Estimate, Sales $17.755M Beat $6.911M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimate of $(1.45) by 3.45 percent. This is a 19.05 percent decrease over losses of $(1.26) per share from the
Benzinga Newsdesk

Earnings Scheduled For February 24, 2026

Benzinga Insights

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved